Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

Park,Se Jung; Kim,Tae Soo; Park,Kyu Hyun; Kwon,Woo Sun; Kim,Jin Ju

doi:10.3892/ol.2020.11549

Serum concentration of sex hormone‑binding globulin in healthy volunteers and patients with breast cancer stratified by sex and age

Authors:
- Se Jung Park
- Tae Soo Kim
- Kyu Hyun Park
- Woo Sun Kwon
- Jin Ju Kim
View Affiliations

Affiliations: Song Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul 03722, Republic of Korea, Department of Laboratory Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea
Published online on: April 21, 2020 https://doi.org/10.3892/ol.2020.11549
Pages: 364-372
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to compare sex hormone-binding globulin (SHBG) levels according to sex (healthy male and female volunteers) and age to determine reference values. Serum SHBG expression levels in patients with breast cancer with different tumor burden states were also determined. A total of 109 samples were obtained from 34 patients in 3 different disease states (non‑tumor, localized tumor and systemic metastasis) during follow‑up. A sandwich ELISA was conducted to measure SHBG, cancer antigen (CA)15‑3 and CA125 expression levels. Wilcoxon rank‑sum tests were performed on non‑normally distributed data and an unpaired t‑test was used for normally distributed variables. SHBG expression levels were higher in females compared with males (P<0.0001). When SHBG expression levels were compared by sex, the difference was maintained in the age groups <30, 30‑39 and ≥50 years, but not in the 40‑49 years group. In males, SHBG expression levels increased until the age of 49 and then decreased (P=0.01). In females, SHBG expression levels exhibited a decreased trend until the age of 49 (P=0.66). In patients with breast cancer, the SHBG expression levels revealed a decreasing trend after the age of 50, which was different compared with the healthy females. There was a decreasing trend of SHBG expression levels from pre‑menopause to post‑menopause healthy volunteers (P=0.74). CA15‑3 (r2=0.07; P=0.59) and CA 125 (r2=‑0.18; P=0.17) levels did not exhibit any significant correlation with SHBG expression levels. There was a significant difference in the SHBG expression levels between male and female healthy volunteers. SHBG expression levels also revealed different patterns between healthy female volunteers and female patients with breast cancer ≥50 years of age. The present study demonstrated that SHBG does not have value as a biomarker, but different reference values according to age and sex may aid in predicting high‑risk groups for hormone‑dependent cancer and guide treatment direction for post‑menopausal breast cancer.

View Figures

View References

1	Selby C: Sex hormone binding globulin: Origin, function and clinical significance. Ann Clin Biochem. 27:532–541. 1990. View Article : Google Scholar : PubMed/NCBI
2	Mousavi Y and Adlercreutz H: Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocellular carcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steriods. 58:301–304. 1993. View Article : Google Scholar
3	Sawada N, Iwasaki M, Inoue M, Sasazuki S, Yamaji T, Shiazu T and Tsugane S; Japan Public Health Center-based Prospective Study Group, : Plasma testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer among Japanese men: A nested case-control study. Cancer Sci. 101:2652–2657. 2010. View Article : Google Scholar : PubMed/NCBI
4	Garcia-Closas M, Brinton LA, Lissowsk J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Zatonski W and Chanock SJ: Ovarian cancer risk and common variation in the sex hormone binding globulin gene: A population-based case-control study. BMC Cancer. 7:602007. View Article : Google Scholar : PubMed/NCBI
5	Grasso M, Buonaguidi A, Mondina R, Borsellino G, Lania C, Banfi G and Rigatti P: Plasma sex hormone binding globulin in patients with prostatic carcinoma. Cancer. 66:354–357. 1990. View Article : Google Scholar : PubMed/NCBI
6	Salonia A, Briganti A, Gallina A, Karakiewicz P, Shariat S, Freschi M, Zann G, Caoitanio U, Bosi E, Rigatti P and Montorsi F: Sex hormone-binding globulin: A novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Urology. 73:850–855. 2009. View Article : Google Scholar : PubMed/NCBI
7	Haapianen R, Rannikko S, Adlercreutz H and Alfthan O: Correlation of pretreatment plasma levels of estradiol and sex-hormone binding globulin-binding capacity with clinical stage and survival of patients with prostate cancer. The Prostate. 8:127–137. 1986. View Article : Google Scholar : PubMed/NCBI
8	Calciano A, Khaw KT, Barrett-Connor E and Garland C: Sex hormones, sex hormone binding globulin, and lung cancer: A 12 year prospective study in a cohort of malesaged 50-79. Br Med J. 296:16401988. View Article : Google Scholar
9	Corbishley TP, Keating JJ, Johnson PJ and Williams R: Serum concentrations of sex hormone binding globulin in lung cancer. Br Med J. 293:792–793. 1986. View Article : Google Scholar
10	Fortunati N, Catalano MG, Boccuzzi G and Fairia R: Sex hormone binding globulin, estradiol and breast cancer. Mol Cell Endocrinol. 316:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
11	Dayalu NSL, Suresh H, Anil KB, Renuka S, Sudershan K and Amitabha R: Sex hormone binding globulin in breast cancer. Indian J Clin Biochemist. 23:25–254. 2008.
12	Catalano MG, Frairia R, Boccuzzi G and Fortunati N: Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells. Mol Cell Endocrinol. 230:31–37. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ratajczak T, Twaddle E and Hähnel R: Sex hormone-binding globulin and estrogen receptor in endometrial and cervical cancer. Gynecol Oncol. 10:262–266. 1980. View Article : Google Scholar : PubMed/NCBI
14	Moore JW, Key TJ, Clark GM, Bulbrook RD, Allen DS, Wang DY and Pike MC: Concentrations of sex hormone-binding globulin (SHBG) in a population of normal females: Relationship to risk factors for breast cancer. Steroids. 52:391–392. 1988. View Article : Google Scholar : PubMed/NCBI
15	Adami HO, Johansson EDB, Vegelius J and Victor A: Serum concentrations of estrone, androstenedione, testosterone and sex hormone-binding globulin in postmenopausal females with breast cancer and in age-matched controls. Upsala J Med Sci. 84:259–274. 1979. View Article : Google Scholar : PubMed/NCBI
16	Moore JW, Clark GM, Bulbrook RD, Hayward JL, Murai JT, Hammond GL and Siiteri PK: Serum concentrations of total and non-protein-bound estradiol in patients with breast cancer and on normal controls. Int J Cancer. 29:17–21. 1982. View Article : Google Scholar : PubMed/NCBI
17	Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P and Pasternack BS: A prospective study of endogenous estrogens and breast cancer in postmenopausal females. J Natl Cancer Inst. 87:190–197. 1995. View Article : Google Scholar : PubMed/NCBI
18	Zeleniucg-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R and Toniolo P: Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer: Longterm results of a prospective study. Br J Cancer. 90:153–159. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lipworth L, Adami HO, Trichopoulos D, Carlstrom K and Mantzoros C: Serum steroid hormone levels, sex-hormone binding globulin and body mass index in the etiology of postmenopausal breast cancer. Epidemiology. 7:96–100. 1996. View Article : Google Scholar : PubMed/NCBI
20	Murayama Y, Utsunomiya J, Takahashi I, Kitamura M and Tominaga T: Sex hormone binding globulin as a reliable indicator of hormone dependence in human breast cancer. Ann Surg. 190:133–138. 1979. View Article : Google Scholar : PubMed/NCBI
21	Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Pommatau E and Saez S: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol. 76:219–226. 1978. View Article : Google Scholar : PubMed/NCBI
22	Wang DY, Rubend RD, Clark GMG, Moore JW and Bulbrook RD: Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer. Breast Cancer Res Treat. 11:67–70. 1988. View Article : Google Scholar : PubMed/NCBI
23	Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N and Hankinson SE: Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst. 98:110–115. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 95:634–635. 2003. View Article : Google Scholar : PubMed/NCBI
25	Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS and Chung HC: Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Lett. 150:137–145. 2000. View Article : Google Scholar : PubMed/NCBI
26	Park HA, Park JK, Park SA and Lee JS: Age, menopause, and cardiovascular risk factors among Korean middle-aged women: The 2005 Korea National Health and Nutrition Examination Survey. J Womens Health (Larchmt). 19:869–876. 2010. View Article : Google Scholar : PubMed/NCBI
27	R Core Team, . R: A language and environment for statistical computing. R Foundation for Statistical Computing. (Vienna). 2012.http://www.R-project.org/
28	RStudio Team, . RStudio: Integrated development for R. RStudio, Inc. (Boston, MA). 2019.http://www.rstudio.com/
29	Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, Choe GY and Hong SK: Pre-operative serum sex hormone-binding globulin as a predictive marker for extra-prostatic extension of tumor in patients with clinically localized prostate cancer. Eur J Urol. 54:1324–1332. 2008. View Article : Google Scholar
30	Nunzio CD, Lombardo R, Albisinni S, Gacci M and Tubaro A: Serum levels of sex hormone binding globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. Int Braz J Urol. 39:793–799. 2013. View Article : Google Scholar : PubMed/NCBI
31	Moore JW, Key TJA, Bulvrook RD, Clark GMG, Allen DS, Wang DY and Pike MC: Sex hormone binding globulin and risk factors for breast cancer in a population of normal females who had never used exogenous sex hormones. Br J Cancer. 56:661–666. 1987. View Article : Google Scholar : PubMed/NCBI
32	Pugeat M, Cousin P, Baret C, Lejeune H and Forest MG: Sex hormone-binding globulin during puberty in normal and hyperandrogenic girls. J Pediatr Endocrinol Metab. 13 (Suppl):1277–1279. 2000.PubMed/NCBI
33	Plymate SR, Stutz FH and Fariss BL: Relationship between sex hormone-binding globulin and estrogen receptors in breast cancer. J Clin Oncol. 2:652–654. 1984. View Article : Google Scholar : PubMed/NCBI
34	He XY, Liao YD, Zhang Y and Wang R: Sex hormone binding globulin and risk of breast cancer in postmenopausal females: A meta-analysis of prospective studies. Horm Metab Res. 47:485–490. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn HJ, Park HK, Noh DY and Hur MH; Korean Breast Cancer Society, : The basic facts of Korean breast cancer in 2011: Results of a nationwide survey and breast cancer registry database. J Breast Cancer. 17:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
36	Fortunati N, Becchis M, Catalano MG, Comba A, Ferrera P, Raineri M, Berta L and Frairia R: Sex hormone-binding globulin, its membrane receptor, and breast cancer: A new approach to the modulation of estradiol action in neoplastic cells. J Steroid Biochem Mol Biol. 69:473–479. 1999. View Article : Google Scholar : PubMed/NCBI
37	Dimou NL, Papadimitriou N, Gill D, Christakoudi S, Murphy N, Gunter MJ, Travis RC, Key TJ, Fortner RT, Haycock PC, et al: Sex hormone binding globulin and risk of breast cancer: A Mendelian randomization study. Int J Epidemiol. 48:807–816. 2019. View Article : Google Scholar : PubMed/NCBI
38	Zhou JY, Shi R, Yu HL, Zheng WL and Ma WL: Association between SHBG Asp327Asn (rs6259) polymorphism and breast cancer risk: A meta-analysis of 10,454 cases and 13,111 controls. Mol Biol Rep. 39:8307–8314. 2012. View Article : Google Scholar : PubMed/NCBI